Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
781.60
+21.74 (+2.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
60
61
Next >
Regeneron Provides Update on Biologics License Application for Linvoseltamab
August 20, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today
↗
August 20, 2024
Via
Benzinga
Biotech Bull Market: 3 Ways To Play It
↗
August 20, 2024
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.
Via
Talk Markets
Topics
Economy
Alphabet Turns Twenty
↗
August 19, 2024
Twenty years ago to the day, the company running the world's largest search engine went public. On August 19th, 2004, Alphabet shares IPO'd at a split-adjusted price of $2.13.
Via
Talk Markets
7 Stocks That Usually Benefit From a Recession
↗
August 13, 2024
These seven stocks have historically shown resilience during economic downturns and could potentially benefit from a recession.
Via
InvestorPlace
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
↗
August 13, 2024
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $15,000 Today
↗
August 08, 2024
Via
Benzinga
3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
↗
August 13, 2024
Investors should closely watch these three biotech stocks as their strong prospects are likely to help the rebound from market volatility.
Via
InvestorPlace
3 Biotech Stocks With Promising Drug Pipelines: August 2024
↗
August 08, 2024
The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval.
Via
InvestorPlace
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
August 07, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Healthcare Stocks Positioned for Possible Market Outperformance
↗
August 07, 2024
While healthcare stocks might not be as shiny as they were in the pandemic era, these three could outperform the broader market.
Via
InvestorPlace
Is Regeneron Pharmaceuticals Due for a Stock Split?
↗
August 03, 2024
Would a stock split help lead Regeneron Pharmaceuticals shares higher?
Via
The Motley Fool
Analyst Ratings For Regeneron Pharmaceuticals
↗
August 02, 2024
Via
Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
↗
July 30, 2024
Via
Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
↗
July 29, 2024
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.
Via
Benzinga
Topics
Economy
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
↗
August 02, 2024
Apple and Meta had strong results, while AI spending remains robust.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
↗
August 01, 2024
Regeneron Pharmaceuticals Q2 results: adjusted EPS of $11.56 (up 13%), revenue of $3.55 billion (up 12%). Key drivers: Eylea HD, Dupixent, and Libtayo. Notable: 18% decline in Eylea US sales; 42%...
Via
Benzinga
Regeneron Stock Climbs After Strong Second-Quarter Performance
↗
August 01, 2024
A strong second-quarter performance lifted the already extended shares of the New York-based drug maker Regeneron.
Via
Investor's Business Daily
Regeneron Reports Second Quarter 2024 Financial and Operating Results
August 01, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
↗
July 22, 2024
Via
Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
↗
July 19, 2024
Via
Benzinga
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
↗
August 01, 2024
Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market...
Via
Benzinga
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
July 31, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
↗
August 01, 2024
After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a...
Via
Benzinga
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
↗
July 27, 2024
These companies are no strangers to beating the market.
Via
The Motley Fool
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
↗
July 25, 2024
Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast.
Via
Benzinga
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
↗
July 23, 2024
MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NSCLC patients. Results include a 38% ORR, 85% DCR, and lower toxicity, with six...
Via
Benzinga
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
↗
July 18, 2024
Johnson & Johnson reports Q2 EPS of $2.82, up 10.2% YoY, beating expectations. Analysts foresee strong MedTech markets ahead, with ongoing M&A strategy emphasizing sustainable growth.
Via
Benzinga
3 Standout Stocks to Buy for the Next Bull Market
↗
July 18, 2024
These standout stocks to buy for a bull market offer promising potential for significant gains as market conditions continue to strengthen.
Via
InvestorPlace
Stocks to Buy: 7 Founder-Led Companies Set to Outperform
↗
July 17, 2024
These founder-led companies are at the forefront of industry innovation, and historical trends indicate that they will likely outperform.
Via
InvestorPlace
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
60
61
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
